Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Alto Neuroscience has a “Moderate Buy” consensus rating from 11 analysts, with eight buys, two holds and one sell. The average 12-month price target is $37.25.
• Several analysts raised their targets, including BTIG Research to $37 from $28, while Wedbush increased its target to $26 and maintained a neutral rating. Institutional investors including Perceptive Advisors and Orbimed Advisors also increased their stakes.
• ANRO recently traded at $36.28, near its 52-week high of $37.48, and reported a quarterly loss of $0.65 per share—better than the $0.73 analyst consensus. Analysts expect a full-year loss of $2.68 per share.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $37.25.

Several equities analysts recently weighed in on the company. Wall Street Zen raised Alto Neuroscience from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. BTIG Research upped their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Wedbush raised their price target on Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research report on Thursday, August 13th. Finally, Wolfe Research initiated coverage on Alto Neuroscience in a research note on Friday, May 22nd. They set an "outperform" rating for the company.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANRO. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company's stock worth $3,786,000 after purchasing an additional 211,222 shares during the last quarter. Jennison Associates LLC purchased a new stake in Alto Neuroscience in the 1st quarter worth approximately $8,687,000. Perceptive Advisors LLC raised its holdings in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after acquiring an additional 225,500 shares during the last quarter. AWM Investment Company Inc. acquired a new position in Alto Neuroscience in the 2nd quarter valued at $2,111,000. Finally, Orbimed Advisors LLC lifted its stake in shares of Alto Neuroscience by 34.0% during the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock worth $3,765,000 after purchasing an additional 42,500 shares during the period.

Alto Neuroscience Stock Down 0.7%

ANRO stock opened at $36.28 on Friday. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The company's 50-day moving average price is $28.53 and its 200 day moving average price is $24.04. Alto Neuroscience has a 52 week low of $3.41 and a 52 week high of $37.48. The company has a market cap of $1.42 billion, a P/E ratio of -14.99 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, research analysts expect that Alto Neuroscience will post -2.68 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source